Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2236-2241

  Tahara, Kouichirou ^a,b,e   Takesako, Kazutoh ^a,b,e   Sette, Alessandro ^c   Celis, Esteban ^d   Kitano, Seigo ^e   Akiyoshi, Tsuyoshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TAKARA SHUZO CO LTD   (Japan)

^c Epimmune   (United States)

^d MAYO CLINIC   (United States)

^e OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; TUMOR VACCINE;

ALLELE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASIAN; CAUCASIAN; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREGULATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RACE DIFFERENCE; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES; FLOW CYTOMETRY; HLA-A ANTIGENS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032792104     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. De Plaen, E., Arden, K., Traversari, C., Gaforio, J. J., Szikora, J-P., De Smet, C., Brasseur, F., van der Bruggen, P., Lethe, B., Lurquin, C., Brasseur, R., Chomez, P., De Backer, O., Cavenee, W., and Boon, T. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics, 40: 360-369, 1994.
2. Van Pel, A., van der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethe, B., Van den Eynde, B., Uyttenhove, C., Renauld, J. C., and Boon, T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev., 145: 229-250, 1995.
3. Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amer-Costesec, A., and Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176: 1445-1457, 1992.
4. Gaugler, B., Van der Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B., Brasseur, F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179: 921-930, 1994.
5. Celis, E., Tsai, V., Crimi, C., DeMars, R., Wentworth, P. A., Chestnut, R. W., Gray, H. M., Sette, A., and Serra, H. M. Induction of antitumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA, 91: 2105-2109, 1994.
6. van der Bruggen, Bastin, J., Gajewski, T., Coulie, P. G., De Smet, C., Traversari, C., Townsend, A., and Boon, T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol., 24: 3038-3043, 1994.
7. Herman, J., van der Bruggen, P., Luescher, I. F., Mandruzzato, S., Romero, P., Thonnard, J., Fleischhauer, K., Boon, T., and Coulie, P. G. A peptide encoded by human gene MAGE-3 and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Immunogenetics, 43: 377-383, 1996.
8. Hu, X., Chakraborty, N. G., Sporn, J. R., Kurtzman, S. H., Ergin, M. T., and Mukherji, B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res., 56: 2479-2483, 1996.
9. Marchand, M., Weynants, P., Rankin, E., Arieti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwijck, R., Humblet, Y., Canon, J-L., Laurent, C., Naeyaert, J-M., Plagne, R., Deraemaecker, R., Knuth, A., Jager, E., Brasseur, F., Herman, J., Coulie, P. G., and Boon, T. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63: 883-885, 1995.
10. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
11. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Lienard, D., Beauduin, M., Dietrich, P-Y., Russo, V., Kerger, J., Masucci, G., Jager, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P. G., van der Bruggen, P., and Boon, T. Tumor regression observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 80: 219-230, 1999.
12. Visseren, M. J. W., van der Burg, S. H., van der Voort, E. I. H., Brandt, R. M. P., Schrier, P. I., van der Bruggen, P., Boon, T., Melief, C. J. M., and Kast, W. M. Identification of HLA-A0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int. J. Cancer, 73: 125-130, 1997.
13. Kawashima, I., Hudson, S. J., Tsai, V., Southwood, S., Takesako, K., Appella, E., Sette, A., and Celis, E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epitherial tumors. Hum. Immunol., 59: 1-14, 1998.
14. Tanaka, F., Fujie, T., Go, H., Baba, K., Mori, M., Takesako, K., and Akiyoshi, T. Efficient induction of anti-tumor cytotoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro. Cancer Immunol. Immunother., 44: 21-26, 1997.
15. Tanaka, F., Fujie, T., Tahara, K., Mori, M., Takesako, K., Sette, A., Celis, E., and Akiyoshi, T. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res., 57: 4465-4468, 1997.
16. Fujie, T., Tahara, K., Tanaka, F., Mori, M., Takesako, K., and Akiyoshi, T. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific antitumor cytotoxic T lymphocytes. Int. J. Cancer, 80: 169-172, 1999.
17. De Smet, C., Lurquin, C., van der Bruggen, P., De Plaen, E., Brasseur, F., and Boon, T. Sequence and expression pattern of the human MAGE-2 gene. Immunogenetics, 39: 121-129, 1994.
18. Dong, R., Kimura, A., Okubo, R., Shinagawa, H., Tamai, H., Nishimura, Y., and Sasazuki, T. HLA-A and DPBI loci confer susceptibility to Graves' disease. Hum. Immunol., 35: 165-172, 1992.
19. Imanishi, T., Akaza, T., Kimura, A., Tokunaga, K., and Gojobori, T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: K. Tsuji, M. Aizawa, and T. Sasazuki (eds.), HLA 1991: Proceeding of the Eleventh International Histocompatibility Workshop and Conference, Vol. 1, pp. 1065-1068. Oxford: Oxford University Press, 1992.
20. Kubo, R. T., Sette, A., Grey, H. M., Appela, E., Sakaguchi, K., Zhu, N. Z., Arnott, D., Sherman, N., Shabonowitz, J., Michael, H., Bondar, W. N., Davis, T. A., and Hunt, D. F. Definition of specific peptide motif for four HLA-A alleles. J. Immunol., 152: 3913-3924, 1994.
21. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
22. Inoue, H., Mori, M., Li, J., Mimori, K., Honda, M., Nakashima, H., Mafune, K., Tanaka, Y., and Akiyoshi, T. Human esophageal carcinomas frequently express tumor-rejection antigens of MAGE genes. Int. J. Cancer, 63: 523-526, 1995.
23. Li, Y., Yang, Y., Fujie, T., Baba, K., Ueo, H., Mori, M., and Akiyoshi, T. Expression of BAGE, GAGE, and MAGE genes in human gastric carcinoma. Clin. Cancer Res., 2: 1619-1625, 1996.
24. Tokunaga, K., Nakamura, Y., Sakata, K., Fujimori, K., Ohkubo, M., Sawada, K., and Sakiyama, S. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res., 47: 5616-5619, 1987.
25. van der Bruggen, P., Szikora, J-P., Boel, P., Wildmann, C., Somville, M., Sensi, M., and Boon, T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanoma expressing HLA-Cw1601. Eur. J. Immunol., 24: 2134-2140, 1994.
26. Brasseur, F., Rimold, D., Lienard, D., Lethe, B., Carrel, S., Arienti, F., Suter, L., Vanwijck, R., Bourlond, A., Humblet, Y., Vacca, A., Conese, M., Lahaye, T., Degiovanni, G., Deraemaecker, R., Beauduin, M., Sastre, X., Salamon, E., Dreno, B., Jager, E., Knuth, A., Chevreau, C., Suciu, S., Lachapelly, J-M., Pouillart, P., Parmiani, G., Lejeune, F., Cerottini, J-C., Boon, T., and Marchand, M. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer, 63: 375-380, 1995.
27. Eura, M., Ogi, K., Chikamatsu, K., Lee, K. D., Nakano, K., Masuyama, K., Itoh, K., and Ishikawa, T. Expression of the MAGE gene family in human head-and-neck squamous-cell carcinoma. Int. J. Cancer, 64: 304-308, 1995.
28. Weynants, P., Lethe, B., Brasseur, F., Marchand, M., and Boon, T. Expression of MAGE genes by non-small-cell lung carcinomas. Int. J. Cancer, 56: 826-829, 1994.
29. Patard, J-J., Brasseur, F., Gil-Diez, S., Radvanyi, F., Marchand, M., Francois, P., Abi-Aad, A., Van Cangh, P., Abbou, C. C., Chopin, D., and Boon, T. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int. J. Cancer, 64: 60-64, 1995.
30. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 3: 321-327, 1998.